Ductal carcinoma in situ: recent history and areas of controversy.

Abstract

The authors provide a perspective on the rapidly evolving field of prognostic analyses designed to quantify the risk of local recurrence in conservatively treated ductal carcinoma in situ (DCIS). These include morphologic features variously defined, nomograms, algorithms and multi-gene expression assays-all of which have completed against the perceived conclusions of the randomized trials of irradiation and Tamoxifen for DCIS: "all subsets benefit". At present the majority of newly diagnosed DCIS can be adequately treated with surgery alone. A number will require irradiation to achieve acceptable local control, and a minority will require mastectomy regardless of adjuvant treatments. Differences in the definition of prognostic factors and in the methods used to establish them is a major reason for the lack of consensus in treatment recommendation.

• Authors: Michael D Lagios, Melvin J Silverstein
• Journal: The breast journal (Breast J) 2015 Jan-Feb Vol. 21 Issue 1 Pg. 21-6 ISSN: 1524-4741 [Electronic] United States
• PMID: 25494706 (Publication Type: Historical Article, Journal Article)
• Copyright: © 2014 Wiley Periodicals, Inc.

Chemical References

• Antineoplastic Agents, Hormonal
• Tamoxifen

Topics

• Algorithms
• Antineoplastic Agents, Hormonal (therapeutic use)
• Breast Neoplasms (genetics, history, therapy)
• Carcinoma, Intraductal, Noninfiltrating (genetics, history, therapy)
• Female
• History, 21st Century
• Humans
• Nomograms
• Prognosis
• Randomized Controlled Trials as Topic
• Tamoxifen (therapeutic use)
• Transcriptome